Коррекция недостаточности лютеиновой фазы у женщин репродуктивного возраста на фоне гипотиреоза

Т. В. Герасимова; Е. Н. Гопчук

doi:10.18370/2309-4117.2014.19.98-101

Authors

Т. В. Герасимова National Medical Academy of Postgraduate Education named after P.L. Shupik, Ukraine
Е. Н. Гопчук National Medical Academy of Postgraduate Education named after P.L. Shupik, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2014.19.98-101

Keywords:

luteal phase defi ciency, hypothyroidism, Tazalok

Abstract

The results of a study on the correction of luteal phase defi ciency (NLF) in women with hypothyroidism using non-hormonal drug complex action Tazalok are presented in the article.

The study included 82 women aged 20 to 38 years with regular menstrual cycles. Women were divided into two clinical groups: 12 (14%) patients with ovulatory menstrual cycle, 70 (83%) woman with NLF. All women with NLF and hypothyroidism we prescribe herbal drug Tazalok at a dosage of 30 drops 3 times a day 30 minutes before meals for 12 weeks to restore the ovulation on the background of hypothyroidism correction to the euthyroid state.

The effi cacy of therapy with Tazalok was obtained in 97% of cases of use, 3% women with severe and persistent anovulation had additional drug therapy.

The study demonstrated that the Tazalok use can effi cient and dynamic improve the quality of women life, and an increased concentration of serum

progesterone during therapy can be recommended this phytogestagen drug as an eff ective for the correction of NLF, including hypothyroidism, as well as relative or absolute giperestrogeniya

Author Biographies

Т. В. Герасимова, National Medical Academy of Postgraduate Education named after P.L. Shupik

PhD, Honored Doctor of Ukraine, assistant professor of the Obstetrics and Gynecology Department number 1

Е. Н. Гопчук, National Medical Academy of Postgraduate Education named after P.L. Shupik

PhD, Obstetrics and Gynecology Department number 1

References

Demina T.N., Goshkoderya I.Y. «Luteal phase defect: new approaches to old problems.» Women’s Health, 4(20) (2004):63-69.
Ventskovskaya I.B., Efymenko O.A. «Hyperprolactinemia in practice gynecologist.» Reproductive Health of Women, 3(2003):71-76.
Chrousos G.P., Torpy D.J., Gold P.W. «Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implication.» Ann. Int. Med, 129(1998):229-240.
Tatarchuk T.F. «Stress and female reproductive function.» International Endocrinology Journal, 3(2006):2-9.
Bauman R.A., Kant G.J. Chronic sustained stress increases levels of anterior pituitary prolactin mRNA. Pharmacol. Biochem. Behav, 67(2000):423-431.
Stocco C., Telleria C., Gibori G. The molecular control of corpus luteum formation, function, and regression. Endocrine reviews, 4(2007):117-149.
Niswander G.D. «Molecular control of Luteal Secretion of Progesterone.» Reproduction, 123(2002):333–339.
Vankov S. «A propos of tribestan pharmacology.» Scientifi c technical report (1980).
Tomova M., Guylemetova R. «Steroid saponin and steroid sapogenine. Furastanol bisglykosid aus Tribulus terrestris L.» Planta medica, 34(1978):188-191.
Kelekci S., Kaya E., Alan M., Alan Y., Bilge U., Mollamahmutoglu L. «Comparison of transvaginal sonography, saline infusion sonography, and offi ce hysteroscopy in reproductive_aged women with or without abnormal uterine bleeding.» Fertil. Steril, 84(2005):682-686.